CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 ---- Advancing four clinical programs for ...

Learn more about whether Recursion Pharmaceuticals, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...

Genetic testing for hereditary arrhythmia and cardiomyopathy in an area with known founder effects on local genetic variants had a high yield in identification of pathogenic variants by taking into ...

University of Florida researchers developed PhyloFrame, a machine-learning tool that uses artificial intelligence to account for ancestral diversity in genetic data.

Most individuals diagnosed with a rare disease won’t live to become teenagers or adults. I knew what I had to do.

While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...

University of Florida researchers are addressing a critical gap in medical genetic research—ensuring it better represents and ...

Beam Therapeutics reports Phase 1/2 trial data showing BEAM-302's potential in AATD treatment, with dose-dependent mutation correction and sustained effects.

Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025Dosing ...

For over a decade, GenomeTrakr has helped scientists trace contaminants from Salmonella to E. coli in the food system.

These discoveries highlight how genetic profiling can play a crucial role in personalizing cancer care,” Ruishan Liu said in ...

Neanderthal fossils show a major population drop 110,000 years ago. Researchers link this to reduced genetic diversity.